Oruka Therapeutics Stock Jumps 12% After Positive Phase 2b Psoriasis Trial
Oruka Therapeutics (ORKA) rose 11.69% to $89.52 after positive Phase 2b trial results for ORKA-001 in psoriasis patients. 61% of high-dose patients achieved complete skin clearance, meeting primary endpoint. The company plans Phase 3 trials in early 2027.
How this was made
The 30-second read
Why it matters
The disclosed Week 16 efficacy (PASI 100 at the high 600 mg dose) and tolerability profile are the immediate catalyst for repricing, with the next decision point being regulator discussions and Phase 3 initiation timing in 1H 2027.
Market read
Traders can reassess Phase 3 probability and timing after a primary-endpoint positive Phase 2b readout with dose-specific PASI 100 responders and no serious treatment-emergent adverse events reported for the high-dose group.
What to watch
Key missing details include placebo arm size, statistical significance language, durability beyond Week 16, and the specific regulatory feedback timeline that could delay Phase 3 start.
Background
Oruka Therapeutics is evaluating ORKA-001 in a Phase 2b trial (EVERLAST-B) for moderate-to-severe plaque psoriasis.
Ticker impact
Oruka Therapeutics shares jumped after EVERLAST-B Phase 2b Week 16 results showed the 600 mg dose met the primary endpoint with 61% PASI 100.
Likely further upside pressure as traders price in higher probability of successful Phase 3 and regulator alignment, despite remaining execution risk.
The article reports primary-endpoint success at Week 16, a high PASI 100 responder rate versus placebo, and no serious treatment-emergent adverse events in the high-dose group.
Market effects
Reinforces investor appetite for dermatology immunology pipelines with clear PASI endpoints, potentially lifting sentiment for psoriasis-focused biotech peers.
Primarily US-listed biotech momentum; limited direct regional spillover beyond Nasdaq biotech trading flows.
Moderate global relevance as psoriasis trial readouts can influence international biotech sentiment, but no cross-border regulatory decision is reported.
Counterpoint
Phase 2b success may not translate to Phase 3, and the article does not provide durability, broader safety signals, or comparative efficacy versus existing standards.
Key entities
- companyOruka Therapeutics, Inc.
Nasdaq-listed biotech whose ORKA-001 Phase 2b psoriasis results drove the stock move.
- drug_candidateORKA-001
Oruka’s investigational therapy evaluated in the EVERLAST-B Phase 2b trial.
- clinical_trialEVERLAST-B Phase 2b trial
Study assessing ORKA-001 in moderate-to-severe plaque psoriasis, with Week 16 results reported.
